Fundraising FoxAbologix
Geneva, CH · 1 known investors
Find your way into Abologix
Sign up to find every way you can get introduced to Abologix
- Your email: who you already know at Abologix, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Abologix team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Abologix is a biopharmaceutical company developing two monoclonal antibodies that target JAM-C and Olfactomedin-like protein 3 (Olfml3) for oncology indications. It is a spin-out from the University of Geneva and Geneva University Hospitals.
Founders & leadership
IF
Ignacio FausFounder
BI
Beat ImhofFounder
TM
Thomas MatthesFounder
Investors · 1
Kickfundlisted by KickfundBasel · $950K
How we know: Kickfund's portfolio page · the VCSheet dataset · Not right? Tell us
In the news
Frequently asked questions
- What does Abologix do?
- Abologix is a biopharmaceutical company developing two monoclonal antibodies that target JAM-C and Olfactomedin-like protein 3 (Olfml3) for oncology indications. It is a spin-out from the University of Geneva and Geneva University Hospitals.
- Who founded Abologix?
- Abologix was founded by Ignacio Faus, Beat Imhof, Thomas Matthes.
- Who are Abologix's investors?
- Abologix's investors include Kickfund.
- Where is Abologix headquartered?
- Abologix is headquartered in Geneva, CH.